CJC-1295
CJC-1295 is a peptide, indexed here under GHRH analogues.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | GHRH analogues |
| CAS registry number | 446262-90-4[1] |
| PubChem CID | 91971820[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C165H269N47O46[1] |
| Molecular weight | 3647.2 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
CJC-1295 is a long-acting growth hormone releasing hormone analogue. A 2005 Endocrinology paper reports that human growth hormone-releasing factor 1-29 albumin bioconjugates activate the GRF receptor, and two 2006 Journal of Clinical Endocrinology and Metabolism papers report prolonged stimulation of growth hormone and IGF-I secretion and the persistence of pulsatile growth hormone secretion during continuous stimulation.
A 2009 Growth Hormone and IGF Research paper reports activation of the GH/IGF-1 axis. A 2010 Drug Testing and Analysis paper reports identification of the compound in an unknown pharmaceutical preparation, which is the context in which much of the analytical literature on this compound sits.
[3, 4, 5, 6, 7]Reported mechanism
A long-acting GHRH analogue that activates the GRF receptor; the retrieved literature attributes its extended duration of action to albumin bioconjugation.
[3, 6]Stated in the titles of the cited 2005 Endocrinology and 2009 Growth Hormone and IGF Research papers.
Targets named in the cited records: GHRH receptor, GH/IGF-1 axis.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
CJC-1295 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- DAC:GRF
- CJC-1295 DAC
- CJC-1295 with DAC
Where this page sits
Research records
Cited research records for CJC-1295, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include CJC-1295
Compounds indexed next to it
- Sermorelin — GHRH analogues
- Tesamorelin — GHRH analogues
Named targets in the cited records
Class page: GHRH analogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for CJC-1295?
CJC-1295 is a long-acting growth hormone releasing hormone analogue. A 2005 Endocrinology paper reports that human growth hormone-releasing factor 1-29 albumin bioconjugates activate the GRF receptor, and two 2006 Journal of Clinical Endocrinology and Metabolism papers report prolonged stimulation of growth hormone and IGF-I secretion and the persistence of pulsatile growth hormone secretion during continuous stimulation.
Which class is CJC-1295 indexed under?
CJC-1295 is indexed under GHRH analogues. GHRH analogues are peptides modelled on growth hormone releasing hormone, which act at the GHRH receptor on the anterior pituitary.
What does the FDA application register show for CJC-1295?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 91971820, Cjc 1295. PubChem, National Library of Medicine (2026). pubchem:91971820
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cjc-1295
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology (2005). pmid:15817669
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab (2006). pmid:16352683
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab (2006). pmid:17018654
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res (2009). pmid:19386527
- Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal (2010). pmid:21204297
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.